Canadian Journal of Gastroenterology and Hepatology

Clinical Study

Effect of Admission Time on the Outcomes of Liver Cirrhosis with Acute Upper Gastrointestinal Bleeding: Regular Hours versus Off-Hours Admission

Table 2

Characteristics of patients with liver cirrhosis and AUGIB after propensity matching in test cohort.


Variables		Propensity matching patients		P value
Variables	Overall (n=226)	Regular hours (n=113)	Off-hours (n=113)	P value

Age (years)	54.51 (6.28-81.62)	54.41 (29.85-81.62)	54.60 (6.28-78.66)	0.829
Sex (male)	144 (63.7%)	73 (64.6%)	71 (62.8%)	0.782
Etiology of Liver Diseases				0.612
HBV	58 (25.7%)	29 (25.7%)	29 (25.7%)
HCV	14 (6.2%)	7 (6.2%)	7 (6.2%)
HBV+ HCV	1 (0.4%)	1 (0.9%)	0 (0%)
Alcohol Abuse	50 (22.1%)	26 (23.0%)	24 (21.2%)
HBV+ Alcohol Abuse	26 (11.5%)	15 (13.3%)	11 (9.7%)
HCV+ Alcohol Abuse	3 (1.3%)	0 (0%)	3 (2.7%)
HBV+ HCV+ Alcohol Abuse	1 (0.4%)	0 (0%)	1 (0.9%)
Drug Related	10 (4.4%)	5 (4.4%)	5 (4.4%)
Autoimmune Liver Diseases	12 (5.3%)	5 (4.4%)	7 (6.2%)
Other or Unclear Etiology	51 (22.6%)	25 (22.1%)	26 (23.0%)
Laboratory Tests
Red Blood Cell (10¹²/L)	2.54 (0.98-5.49)	2.60 (0.98-5.49)	2.53 (1.15-4.68)	0.989
Hemoglobin (g/L)	71.50 (23.00-157.00)	72.00 (23.00-157.00)	71.00 (23.00-133.00)	0.901
White Blood Cell (10⁹/L)	4.30 (1.00-26.30)	4.10 (1.10-26.30)	4.40 (1.00-17.50)	0.239
Platelet Count (10⁹/L)	74.00 (17.00-435.00)	72.00 (27.00-303.00)	79.00 (17.00-435.00)	0.538
Total Bilirubin (umol/L)	18.80 (3.30-187.40)	19.00 (6.10-90.40)	18.40 (3.30-187.40)	0.669
Direct Bilirubin (umol/L)	7.50 (0.50-151.60)	7.50 (1.30-56.30)	7.20 (0.50-151.60)	0.384
Indirect Bilirubin (umol/L)	11.35 (2.40-56.80)	11.20 (3.20-41.10)	11.40 (2.40-56.80)	0.771
Albumin (g/L)	30.10 (10.00-49.30)	30.48 (10.50-49.30)	29.40 (10.00-45.60)	0.580
Alanine Aminotransferase (U/L)	23.00 (5.00-234.00)	23.00 (6.00-234.00)	23.00 (5.00-154.00)	0.896
Aspartate Aminotransferase (U/L)	31.00 (9.00-263.00)	31.00 (12.00-263.00)	31.00 (9.00-175.00)	0.872
Alkaline Phosphatase (U/L)	74.00 (17.44-707.00)	77.00 (17.44-707.00)	71.00 (21.00-685.00)	0.282
Gamma-glutamyl Transpeptidase (U/L)	36.00 (8.00-1168.00)	45.00 (8.00-1168.00)	33.00 (9.00-737.00)	0.354
Blood Urea Nitrogen (mmol/L)	7.62 (1.96-34.00)	7.66 (2.04-34.00)	7.61 (1.96-28.10)	0.989
Serum Creatinine (umol/L)	60.00 (28.00-234.00)	60.00 (28.00-225.70)	59.00 (30.50-234.00)	0.655
Potassium (mmol/L)	4.06 (2.90-5.50)	4.05 (3.00-5.50)	4.08 (2.90-5.50)	0.285
Sodium (mmol/L)	138.50 (128.00-150.00)	138.30 (130.40-148.00)	138.50 (128.00-150.00)	0.773
PT (seconds)	15.80 (11.00-46.30)	15.60 (12.10-36.10)	16.00 (11.00-46.30)	0.912
APTT (seconds)	39.55 (27.30-66.80)	40.10 (28.20-66.80)	38.50 (27.30-63.90)	0.253
INR	1.28 (0.79-4.77)	1.26 (0.90-3.57)	1.29 (0.79-4.77)	0.950
Child-Pugh Score	7.00 (5.00-13.00)	7.00 (5.00-12.00)	7.00 (5.00-13.00)	0.891
Child-Pugh A/B/C	72 (31.9%)/121 (53.5%)/33 (14.6%)	35 (31.0%)/64 (56.6%)/14 (12.4%)	37 (32.7%)/57 (50.5%)/19 (16.8%)	0.544
MELD Score	6.12 (-7.14-21.56)	6.12 (-5.03-20.16)	5.68 (-7.14-21.56)	0.733
Recalibrated MELD Score	-4.05 (-6.79 - -0.85)	-4.04 (-6.35 - -1.14)	-4.14 (-6.79 - -0.85)	0.733
ALBI Score	-1.70 (-3.23-0.22)	-1.70 (-3.23 - -0.43)	-1.69 (-3.06-0.22)	0.767
Esophageal Varices (No/Mild/Moderate/Severe)	11 (4.9%)/10 (4.4%)/23 (10.2%)/182 (80.5%)	5 (4.4%)/5 (4.4%)/11 (9.8%)/92 (81.4%)	6 (5.3%)/5 (4.4%)/12 (10.6%)/90 (79.7%)	0.984
Treatment
Endoscopic Treatment	191 (84.5%)	96 (85.0%)	95 (84.1%)	0.854
Sengstaken Blakemore	8 (3.5%)	5 (4.4%)	3 (2.7%)	0.472
Somatostatin and/or Octreotide	218 (96.5%)	107 (94.7%)	111 (98.2%)	0.150
Blood Transfusion	159 (70.4%)	80 (70.8%)	79 (69.9%)	0.884
PPIs	226 (100%)	113 (100%)	113 (100%)	NA
Surgery	1 (0.4%)	1 (0.9%)	0 (0%)	0.316
5-day Re-bleeding After Treatment	32 (14.2%)	14 (12.4%)	18 (15.9%)	0.445
Death During Hospitalization	5 (2.2%)	2 (1.8%)	3 (2.7%)	0.651
Length of Stay (days)	12.835 (2.76-78.00)	12.97 (3.91-78.00)	12.41 (2.76-45.26)	0.229
Total Payment (¥)	28,633.075 (2,776.55-143,048.30)	26,733.81 (2,776.55-115,201.67)	29,361.51 (5,856.09-143,048.30)	0.390

Data are expressed as median (range) or frequency (percentage).
Abbreviations. AUGIB: acute upper gastrointestinal bleeding; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PT, prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; MELD: model for end-stage liver disease; ALBI: albumin-bilirubin; PPIs: Proton pump inhibitors; ¥, Renminbi.